Diagnosing Frontotemporal Lobar Degeneration

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-08-31

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To establish diagnostic tools to make an accurate clinical and pathological diagnosis of patients with clinical FTLD syndromes

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Sunnybrook Dementia Study

NCT01800214

Dementia

RECRUITING

Multimodal Ocular Imaging in Neurodegeneration

NCT03699644

Alzheimer Disease Alzheimer Dementia Frontotemporal Dementia

COMPLETED

Neuroinflammation in FTLD

NCT06870838

Corticobasal Syndrome(CBS) Primary Progressive Aphasia(PPA) Progressive Supranuclear Palsy(PSP) +2 more

ACTIVE_NOT_RECRUITING

Metabolic Characterization of Alzheimer's Disease and Frontotemporal Dementia by 23Na-MRI and FDG-PET

NCT07100470

FTD AD Healthy Controls

NOT_YET_RECRUITING NA

Natural History Characterization in Symptomatic and Asymptomatic Progranuline Gene Mutation Carriers

NCT04014673

Frontotemporal Lobar Degeneration

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The goal of this study is to determine the best diagnostic test for diagnosing frontotemporal lobar degeneration. To accomplish this, the current study will evaluate different tests: brain imaging, skin biopsy, body fluid samples (blood and cerebrospinal fluid), thinking abilities, everyday functioning, and brain autopsy. The study team hopes that this information can be used to guide diagnosis and further understanding of mechanism of disease in Frontotemporal Lobar Degeneration and possibly treatment in the future.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Corticobasal Syndrome Progressive Supranuclear Palsy Behavioral Variant Frontotemporal Dementia Semantic Dementia Progressive Nonfluent Aphasia Amyotrophic Lateral Sclerosis And/or Frontotemporal Dementia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Progressive supranuclear palsy

Observational Study

Intervention Type OTHER

Corticobasal syndrome

Observational Study

Intervention Type OTHER

Behavoral variant FTD

Observational Study

Intervention Type OTHER

Semantic variant PPA

Observational Study

Intervention Type OTHER

Non-fluent variant PPA

Observational Study

Intervention Type OTHER

FTD-motor neuron disease

Observational Study

Intervention Type OTHER

Healthy controls

Observational Study

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Observational Study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant must have a reliable study partner who can provide an independent evaluation of functioning.
* Able to read, understand and speak English for neuropsychological testing.
* Control subjects must have a normal neurological exam, a CDR sum of boxes = 0, and MMSE score equal to or greater than 28

Exclusion Criteria

* Patients with clinical, imaging or CSF A beta/ tau profile consistent with AD
* History of traumatic brain injury, brain tumors, stroke or other neurological or psychiatric disorders that can explain symptoms will be excluded.
* Premenopausal women will be asked to consent to a pregnancy test prior to each scan as pregnant women will be excluded from study because of potential harm to fetus from PET study.
* Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body.

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes